Christine Lind

Christine Lind (chief executive) discloses dealings in 2 companies, chiefly Bactiguard Holding AB and XSpray Pharma AB (publ). In total, 6 filings cover trades dated from 16 December 2024 to 9 September 2025.

On the market, this insider has only ever bought: 5 purchases, €259k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. So far in 2025, the count stands at 5 purchases and no sales.

Half of the purchases are above €3,187 and half below. Measured against the company's value, the median purchase equals 0.0064% of market capitalisation, across 5 purchases where it is known. The 5 purchases reviewed show no overlap with other insiders buying the same stock within a month.

The newest entry dates from 12 September 2025: a transaction of €592, in XSpray Pharma AB (publ). The latest purchase dates back some time: it was published 437 days ago, on 7 August 2025. Between a trade and the moment it shows up on Finansinspektionen, the median delay is 1 day. Under the Market Abuse Regulation, managers have three business days to notify their trades. Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.